<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<measures><measure><type>Main</type><parent-measure></parent-measure><title>Total number of samples found to be violative and forwarded for review and regulatory follow-up in the month</title><dictionary>Violative samples are Class 3 samples that fail to meet established standards and policy guidelines. Violative results are forwarded to the local Compliance Branch or the responsible regulatory center for a recommendation of regulatory action.</dictionary><footnotes><note></note></footnotes><measure-description>Number of Violative Samples</measure-description><chart-type>column</chart-type><chart-color></chart-color><right-min></right-min><right-max></right-max><fiscal-year><chart-min>0</chart-min><chart-max>350</chart-max><title>2010</title><target-header></target-header><target-description></target-description><summary>FY 2010 Overall: 3,070</summary><time><frame>Oct 2009</frame><target></target><value>230</value></time><time><frame>Nov 2009</frame><target></target><value>230</value></time><time><frame>Dec 2009</frame><target></target><value>252</value></time><time><frame>Jan 2010</frame><target></target><value>188</value></time><time><frame>Feb 2010</frame><target></target><value>247</value></time><time><frame>Mar 2010</frame><target></target><value>299</value></time><time><frame>Apr 2010</frame><target></target><value>221</value></time><time><frame>May 2010</frame><target></target><value>209</value></time><time><frame>Jun 2010</frame><target></target><value>314</value></time><time><frame>Jul 2010</frame><target></target><value>306</value></time><time><frame>Aug 2010</frame><target></target><value>282</value></time><time><frame>Sep 2010</frame><target></target><value>292</value></time></fiscal-year><fiscal-year><chart-min>0</chart-min><chart-max>350</chart-max><title>2011</title><target-header></target-header><target-description></target-description><summary>FY 2011 Total: 3,775</summary><time><frame>Oct 2010</frame><target></target><value>309</value></time><time><frame>Nov 2010</frame><target></target><value>319</value></time><time><frame>Dec 2010</frame><target></target><value>247</value></time><time><frame>Jan 2011</frame><target></target><value>298</value></time><time><frame>Feb 2011</frame><target></target><value>321</value></time><time><frame>Mar 2011</frame><target></target><value>360</value></time><time><frame>Apr 2011</frame><target></target><value>297</value></time><time><frame>May 2011</frame><target></target><value>302</value></time><time><frame>Jun 2011</frame><target></target><value>243</value></time><time><frame>Jul 2011</frame><target></target><value>330</value></time><time><frame>Aug 2011</frame><target></target><value>388</value></time><time><frame>Sep 2011</frame><target></target><value>361</value></time></fiscal-year><fiscal-year><chart-min></chart-min><chart-max></chart-max><title>2012</title><target-header></target-header><target-description></target-description><summary>FY 2012 YTD: 838 </summary><time><frame>Oct 2011</frame><target></target><value>252</value></time><time><frame>Nov 2011</frame><target></target><value>320</value></time><time><frame>Dec 2011</frame><target></target><value>266</value></time><time><frame>Jan 2012</frame><target></target><value></value></time><time><frame>Feb 2012</frame><target></target><value></value></time><time><frame>Mar 2012</frame><target></target><value></value></time><time><frame>Apr 2012</frame><target></target><value></value></time><time><frame>May 2012</frame><target></target><value></value></time><time><frame>Jun 2012</frame><target></target><value></value></time><time><frame>Jul 2012</frame><target></target><value></value></time><time><frame>Aug 2012</frame><target></target><value></value></time><time><frame>Sep 2012</frame><target></target><value></value></time></fiscal-year></measure><related-links><link><url>http://www.fda.gov/AboutFDA/Transparency/track/ucm227871.htm</url><text>FDA-TRACK ORA Laboratories Dashboard</text></link></related-links><glossary></glossary></measures>
    






